The impact of hyperbaric oxygen treatment for cardiovascular implantable electronic devices

The safety of hyperbaric oxygen treatment (HBO2) in patients with cardiovascular implanted electronic devices (CIED) remains unclear. We conducted a retrospective analysis of seven CIED patients (median age 79 [73–83] years, five males [71.4%]), including five with pacemakers and two with implantable cardioverter defibrillators (ICD), who underwent HBO2between June 2013 and April 2023. During the initial session, electrocardiogram monitoring was conducted, and CIED checks were performed before and after the treatment. In addition, the medical records were scrutinized to identify any abnormal CIED operations. All seven CIED patients underwent HBO2within the safety pressure range specified by the CIED manufacturers or general pressure test by the International Organization for Standardization (2.5 [2.5–2.5] atmosphere absolute × 18 [5–20] sessions). When comparing the CIED parameters before and after HBO2, no significant changes were observed in the waveform amplitudes, pacing thresholds, lead impedance of the atrial and ventricular leads, or battery levels. All seven patients, including two with the rate response function activated, exhibited no significant changes in the pacing rate or pacing failure. Two ICD patients did not deactivate the therapy, including the defibrillation; however, they did not experience any arrhythmia or inappropriate ICD therapy during the HBO2. CIED patients who underwent HBO2within the safety pressure range exhibited no significant changes in the parameters immediately after the HBO2and had no observable abnormal CIED operations during the treatment. The safety of defibrillation by an ICD during HBO2should be clarified. The patients with CIEDs who underwent HBO2within the safety pressure range specified by the ICD manufacturers showed no significant changes in the CIED parameters before or immediately after HBO2, and there were no observable abnormalities in the CIED operation during HBO2.